Prospective randomized study of clomiphene citrate and gonadotrophins versus goserelin and gonadotrophins for follicular stimulation in assisted reproduction.

Dhont M, Onghena A, Coetsier T, De Sutter P

Human reproduction (Oxford, England)1 Apr 1995Cited by 24 (Europe PMC)

PMID7650122DOI10.1093/oxfordjournals.humrep.a136039PepBankPUB-07650122

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In assisted reproduction, goserelin with HMG increased pregnancy per cycle versus clomiphene citrate with HMG (36.8 versus 24.5%, P < 0.02).
In plain wordsIn assisted reproduction, pregnancy per cycle was higher with goserelin and HMG than with clomiphene citrate and HMG.
Peptide
Goserelin
Outcome
IncreasePregnancy per cycle, all procedures
Study
n: not reported in source
Comparator
Clomiphene citrate with HMG
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Pregnancy rate per cycle, all procedures
36.8%
goserelin/HMG
Pregnancy rate per cycle, all procedures
24.5%
clomiphene citrate/HMG
P value
< 0.02 p
goserelin/HMG vs clomiphene citrate/HMG
Source sentences
Summary
The pregnancy rates per cycle were significantly better in the goserelin/HMG group than in the clomiphene citrate/HMG group, both for all procedures of assisted reproduction combined (36.8 versus 24.5%; P < 0.02)
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a prospective randomized study of goserelin, a long-acting gonadotrophin-releasing hormone agonist (GnRHa) and human menopausal gonadotrophin (HMG) versus clomiphene citrate and HMG for follicular stimulation in assisted reproduction
Report a problemFND-0765012201
02HumanRandomized controlled trialEfficacy outcome
In IVF, pregnancy per cycle was higher with goserelin and HMG than with clomiphene citrate and HMG (37.0 versus 23.5%, P < 0.02).
In plain wordsIn IVF, pregnancy per cycle was higher with goserelin and HMG than with clomiphene citrate and HMG.
Peptide
Goserelin
Outcome
IncreasePregnancy per cycle, IVF
Study
n: not reported in source
Comparator
Clomiphene citrate with HMG
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Pregnancy rate per cycle, IVF
37%
goserelin/HMG
Pregnancy rate per cycle, IVF
23.5%
clomiphene citrate/HMG
P value
< 0.02 p
goserelin/HMG vs clomiphene citrate/HMG
Source sentences
Summary
The pregnancy rates per cycle were significantly better in the goserelin/HMG group than in the clomiphene citrate/HMG group, both for all procedures of assisted reproduction combined (36.8 versus 24.5%; P < 0.02) and for the main procedure of in-vitro fertilization (IVF) (37.0 versus 23.5%; P < 0.02).
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a prospective randomized study of goserelin, a long-acting gonadotrophin-releasing hormone agonist (GnRHa) and human menopausal gonadotrophin (HMG) versus clomiphene citrate and HMG for follicular stimulation in assisted reproduction
Report a problemFND-0765012202
03HumanRandomized controlled trialEfficacy outcome
In assisted reproduction, pregnancy per oocyte retrieval did not differ significantly between goserelin/HMG and clomiphene citrate/HMG (37.8 versus 30.8%, P = 0.40).
In plain wordsIn assisted reproduction, pregnancy per oocyte retrieval did not differ significantly between goserelin/HMG and clomiphene citrate/HMG.
Peptide
Goserelin
Outcome
No significant changePregnancy per oocyte retrieval
Study
n: not reported in source
Comparator
Clomiphene citrate with HMG
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Pregnancy rate per oocyte retrieval
37.8%
goserelin/HMG
Pregnancy rate per oocyte retrieval
30.8%
clomiphene citrate/HMG
P value
0.4 p
goserelin/HMG vs clomiphene citrate/HMG
Source sentences
Summary
Differences in pregnancy rates per oocyte retrieval and per embryo transfer were less pronounced (37.8 versus 30.8%; P = 0.40 and 44.4 versus 36.8%; not significant).
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a prospective randomized study of goserelin, a long-acting gonadotrophin-releasing hormone agonist (GnRHa) and human menopausal gonadotrophin (HMG) versus clomiphene citrate and HMG for follicular stimulation in assisted reproduction
Report a problemFND-0765012203
04HumanRandomized controlled trialEfficacy outcome
In assisted reproduction, pregnancy per embryo transfer did not differ significantly between goserelin/HMG and clomiphene citrate/HMG (44.4 versus 36.8%).
In plain wordsIn assisted reproduction, pregnancy per embryo transfer did not differ significantly between goserelin/HMG and clomiphene citrate/HMG.
Peptide
Goserelin
Outcome
No significant changePregnancy per embryo transfer
Study
n: not reported in source
Comparator
Clomiphene citrate with HMG
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Pregnancy rate per embryo transfer
44.4%
goserelin/HMG
Pregnancy rate per embryo transfer
36.8%
clomiphene citrate/HMG
Source sentences
Summary
Differences in pregnancy rates per oocyte retrieval and per embryo transfer were less pronounced (37.8 versus 30.8%; P = 0.40 and 44.4 versus 36.8%; not significant).
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a prospective randomized study of goserelin, a long-acting gonadotrophin-releasing hormone agonist (GnRHa) and human menopausal gonadotrophin (HMG) versus clomiphene citrate and HMG for follicular stimulation in assisted reproduction
Report a problemFND-0765012204
05HumanRandomized controlled trialEfficacy outcome
In assisted reproduction, goserelin/HMG required more HMG ampoules than clomiphene citrate/HMG (44.9 versus 9.9, P < 0.0001).
In plain wordsIn assisted reproduction, goserelin/HMG required more HMG ampoules than clomiphene citrate/HMG.
Peptide
Goserelin
Outcome
IncreaseHMG ampoules
Study
n: not reported in source
Comparator
Clomiphene citrate with HMG
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
HMG ampoules
44.9 ampoules
goserelin/HMG group
HMG ampoules
9.9 ampoules
clomiphene citrate/HMG group
Source sentences
Summary
On the other hand, stimulation with goserelin/HMG was associated with a higher number of ampoules of HMG (44.9 versus 9.9; P < 0.0001)
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a prospective randomized study of goserelin, a long-acting gonadotrophin-releasing hormone agonist (GnRHa) and human menopausal gonadotrophin (HMG) versus clomiphene citrate and HMG for follicular stimulation in assisted reproduction
Report a problemFND-0765012205
06HumanRandomized controlled trialEfficacy outcome
In assisted reproduction, stimulation lasted longer with goserelin/HMG than clomiphene citrate/HMG (11.2 versus 8.7 days, P < 0.0001).
In plain wordsIn assisted reproduction, stimulation lasted longer with goserelin/HMG than clomiphene citrate/HMG.
Peptide
Goserelin
Outcome
IncreaseStimulation duration
Study
n: not reported in source
Comparator
Clomiphene citrate with HMG
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Duration of stimulation
11.2 days
goserelin/HMG group
Duration of stimulation
8.7 days
clomiphene citrate/HMG group
Source sentences
Summary
a longer duration of stimulation (11.2 versus 8.7 days; P < 0.0001)
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a prospective randomized study of goserelin, a long-acting gonadotrophin-releasing hormone agonist (GnRHa) and human menopausal gonadotrophin (HMG) versus clomiphene citrate and HMG for follicular stimulation in assisted reproduction
Report a problemFND-0765012206
07HumanRandomized controlled trialSafety outcome
In assisted reproduction, ovarian stimulation incidence was 4.5% (7/154) with goserelin/HMG versus 0% with clomiphene citrate/HMG.
In plain wordsIn assisted reproduction, ovarian stimulation incidence was higher with goserelin/HMG than clomiphene citrate/HMG.
Peptide
Goserelin
Outcome
IncreaseOvarian stimulation incidence
Study
n: not reported in source
Comparator
Clomiphene citrate with HMG
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Incidence of ovarian stimulation
4.5%
goserelin/HMG group
Ovarian stimulation events
7 patients
goserelin/HMG group, of 154
Incidence of ovarian stimulation
0%
clomiphene citrate/HMG group
Source sentences
Summary
an incidence of ovarian stimulation of 4.5% (7/154) versus 0% in the clomiphene citrate/HMG group.
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a prospective randomized study of goserelin, a long-acting gonadotrophin-releasing hormone agonist (GnRHa) and human menopausal gonadotrophin (HMG) versus clomiphene citrate and HMG for follicular stimulation in assisted reproduction
Report a problemFND-0765012207

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.